| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-03-10 |
| タイトル |
|
|
タイトル |
Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Bone metabolic marker |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Bone mineral density |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Bone scan index |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Prostate cancer |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Radium-223 |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
Shiota, Masaki
Enokida, Hideki
Murakami, Yoji
賀本, 敏行
WEKO
9783
e-Rad_Researcher
00281098
| ja |
賀本, 敏行
宮崎大学
|
| ja-Kana |
カモト, トシユキ
|
| en |
Kamoto, Toshiyuki
University of Miyazaki
|
Search repository
Igawa, Tsukasa
Masumori, Naoya
Uemura, Hirotsugu
Mitsunari, Kensuke
Sumiyoshi, Takayuki
Uemura, Hiroji
Higashijima, Katsuyoshi
| en |
Higashijima, Katsuyoshi（Personal）
University of Occupational and Environmental Health
|
Search repository
Tokunaga, Shoji
Isoda, Takuro
Ishigami, Kousei
Eto, Masatoshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Abstract
Background
Radium-223 dichloride (Ra-223) improves survival in men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, but its interaction with bone-modifying agents remains unclear.
Methods
The KYUCOG-1901 prospective multicenter study enrolled Japanese men with mCRPC and bone metastases treated with up to six cycles of Ra-223. Serial assessments included bone scan index (BSI), serum bone metabolic markers (BMMs; BAP, P1NP, and TRACP-5b), and bone mineral density (BMD) from baseline (BL) through one year. Clinical outcomes including radiographic progression-free survival (rPFS), time to symptomatic skeletal event and overall survival were assessed by BSI and serum BMMs.
Results
BSI remained stable throughout treatment and follow-up. High BL BSI predicted early discontinuation and shorter rPFS, and increases in BSI correlated with worse rPFS. BAP exhibited a transient decline in patients treated with and without bone-modifying agents (BMAs), while TRACP-5b declined in those receiving BMAs. Elevated BAP at BL and BMMs at end of treatment, and increases in P1NP during therapy, were associated with rPFS. Lumbar spine BMD increased modestly over 1 year in both patients treated with and without BMAs, while femoral BMD remained unchanged.
Conclusion
Ra-223 stabilized skeletal tumor burden, transiently suppressed serum BMMs, and improved lumbar BMD in men with mCRPC. BSI and serum BMMs provided prognostic information, supporting their integration into longitudinal monitoring. These findings highlight the potential of combining Ra-223 with bone-modifying agents to optimize outcomes. |
|
言語 |
en |
| 書誌情報 |
en : European journal of nuclear medicine and molecular imaging
発行日 2026-02-10
|
| 出版者 |
|
|
出版者 |
Springer Science and Business Media LLC |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
16197089 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s00259-026-07807-4 |
| 権利 |
|
|
権利情報 |
© The Author(s) 2026 |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
Fultext (1.5 MB)
.png)
